Impel Pharmaceuticals
Seattle
About Impel Pharmaceuticals
Impel Pharmaceuticals is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $261.3M
- Funding stage: IPO
- Last round: Post-IPO Debt (Mar 2022)
- Ticker: nasdaq:IMPL
- Website: impelnp.com
- Phone: 2067261217
Industries & Categories
Biotechnology, Delivery, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/impel-pharmaceuticals-39664 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.